HBV and HCV Infection Prophylaxis in Liver Transplant Recipients

Author:

Mihăilă Mariana,Mădălina Pascu Cristina,Andrunache Andreea,Ștefan Ghenea Cătălin

Abstract

Liver transplantation is the treatment of choice for patients with liver cirrhosis caused by viruses (HCV, HBV, and HBV + HDV) in end-stage liver disease. However, liver transplantation is complicated by the risk of recurrent infection, which significantly affects the graft and patient survival, the main risk factor for the development of recurrent viral infection being the viral load at the time of transplant. The development of antiviral drugs and effective prophylactic regimens using hepatitis B immunoglobulins have significantly improved hepatitis B outcomes after liver transplantation. Hepatitis B virus (HBV) reinfection after liver transplantation (LT) may favor the recurrence of hepatocellular carcinoma (HCC), and combination therapy with hepatitis B immunoglobulin (HBIG) and nucleoside/nucleotide analog may reduce HBV recurrence after LT. In patients transplanted for HCV infection due to the availability of direct-acting antivirals, the survival of transplanted patients is comparable to that of transplants performed for alcoholic liver disease and even better than the survival evaluated in patients with hemochromatosis or hepatitis B infection. However, current approaches continue to be hampered by the extremely high cost of treatment and the emergence of drug-resistant viral mutations.

Publisher

IntechOpen

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3